ArticlePloS one2015
Aureonitol, a Fungi-Derived Tetrahydrofuran, Inhibits Influenza Replication by Targeting Its Surface Glycoprotein Hemagglutinin.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Deoxyshikonin Inhibits Influenza A Virus Infection at an Early Stage.International journal of molecular sciences · 2025Article
- Anti-Viral Activity of Conessine Against Influenza A Virus.International journal of molecular sciences · 2025Article
- Antiviral Activity of Berbamine Against Influenza A Virus Infection.International journal of molecular sciences · 2025Article
- The biology of the avian influenza virus: A comprehensive review with insights into novel therapeutic strategies.Open veterinary journal · 2025Review
- Review
- Antiviral Effect of Ginsenosides rk1 against Influenza a Virus Infection by Targeting the Hemagglutinin 1-Mediated Virus Attachment.International journal of molecular sciences · 2023Article
- Review
- Drug update - Baloxavir marboxil: Latest entrant into the arena of pharmacotherapy of influenza.Medical journal, Armed Forces India · 2022Review
- Small Molecule Inhibitors of Influenza Virus Entry.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Emerging paradigms of viral diseases and paramount role of natural resources as antiviral agents.The Science of the total environment · 2021Review
- The emerging influenza virus threat: status and new prospects for its therapy and control.Archives of virology · 2018Review
- Antiviral Agents From Fungi: Diversity, Mechanisms and Potential Applications.Frontiers in microbiology · 2018Review
- Article
- Trienylfuranol A and trienylfuranone A-B: metabolites isolated from an endophytic fungus, Hypoxylon submoniticulosum, in the raspberry Rubus idaeus.The Journal of antibiotics · 2017Article
- Decarboxylative alkenylation.Nature · 2017Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The influenza virus causes acute respiratory infections, leading to high morbidity and mortality in groups of patients at higher risk. Antiviral drugs represent the first line of defense against influenza, both for seasonal infections and pandemic outbreaks. Two main classes of drugs against influenza are in clinical use: M2-channel blockers and neuraminidase inhibitors. Nevertheless, because influenza strains that are resistant to these antivirals have been described, the search for novel compounds with different mechanisms of action is necessary. Here, we investigated the anti-influenza activity of a fungi-derived natural product, aureonitol. This compound inhibited influenza A and B virus replication. This compound was more effective against influenza A(H3N2), with an EC50 of 100 nM. Aureonitol cytoxicity was also very low, with a CC50 value of 1426 μM. Aureonitol inhibited influenza hemagglutination and, consequently, significantly impaired virus adsorption. Molecular modeling studies revealed that aureonitol docked in the sialic acid binding site of hemagglutinin, forming hydrogen bonds with highly conserved residues. Altogether, our results indicate that the chemical structure of aureonitol is promising for future anti-influenza drug design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.